139 related articles for article (PubMed ID: 15612662)
1. Genetic polymorphism analysis of cytochrome P4502C19 in Chinese Uigur and Han populations.
Niu CY; Luo JY; Hao ZM
Chin J Dig Dis; 2004; 5(2):76-80. PubMed ID: 15612662
[TBL] [Abstract][Full Text] [Related]
2. Genotyping of S-mephenytoin 4'-hydroxylation in an extended Japanese population.
Kubota T; Chiba K; Ishizaki T
Clin Pharmacol Ther; 1996 Dec; 60(6):661-6. PubMed ID: 8988068
[TBL] [Abstract][Full Text] [Related]
3. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese.
De Morais SM; Wilkinson GR; Blaisdell J; Meyer UA; Nakamura K; Goldstein JA
Mol Pharmacol; 1994 Oct; 46(4):594-8. PubMed ID: 7969038
[TBL] [Abstract][Full Text] [Related]
4. Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele.
Xiao ZS; Goldstein JA; Xie HG; Blaisdell J; Wang W; Jiang CH; Yan FX; He N; Huang SL; Xu ZH; Zhou HH
J Pharmacol Exp Ther; 1997 Apr; 281(1):604-9. PubMed ID: 9103550
[TBL] [Abstract][Full Text] [Related]
5. Genetic polymorphism of CYP2C19 and lansoprazole pharmacokinetics in Japanese subjects.
Katsuki H; Nakamura C; Arimori K; Fujiyama S; Nakano M
Eur J Clin Pharmacol; 1997; 52(5):391-6. PubMed ID: 9272410
[TBL] [Abstract][Full Text] [Related]
6. [Comparison of genetic polymorphism of cytochrome CYP2C19 between men and women in Chinese population].
Fu LQ; Huang F; Wu DZ; Guo JH
Yao Xue Xue Bao; 2004 Mar; 39(3):161-3. PubMed ID: 15171646
[TBL] [Abstract][Full Text] [Related]
7. Genetic analysis of the S-mephenytoin polymorphism in a Chinese population.
de Morais SM; Goldstein JA; Xie HG; Huang SL; Lu YQ; Xia H; Xiao ZS; Ile N; Zhou HH
Clin Pharmacol Ther; 1995 Oct; 58(4):404-11. PubMed ID: 7586932
[TBL] [Abstract][Full Text] [Related]
8. Linkage of mutant alleles of CYP2C18 and CYP2C19 in a Japanese population.
Kubota T; Hibi N; Chiba K
Biochem Pharmacol; 1998 Jun; 55(12):2039-42. PubMed ID: 9714325
[TBL] [Abstract][Full Text] [Related]
9. Evidence that poor metabolizers of (S)-mephenytoin could be identified by haplotypes of CYP2C19 in Japanese.
Takakubo F; Kuwano A; Kondo I
Pharmacogenetics; 1996 Jun; 6(3):265-7. PubMed ID: 8807668
[TBL] [Abstract][Full Text] [Related]
10. CYP2C19 genotyping and associated mephenytoin hydroxylation polymorphism in a Canadian Inuit population.
Jurima-Romet M; Goldstein JA; LeBelle M; Aubin RA; Foster BC; Walop W; Rode A
Pharmacogenetics; 1996 Aug; 6(4):329-39. PubMed ID: 8873219
[TBL] [Abstract][Full Text] [Related]
11. Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4'-hydroxylation activities in livers of Japanese and Caucasian populations.
Inoue K; Yamazaki H; Imiya K; Akasaka S; Guengerich FP; Shimada T
Pharmacogenetics; 1997 Apr; 7(2):103-13. PubMed ID: 9170147
[TBL] [Abstract][Full Text] [Related]
12. [Cytochrome P450 2C19 gene polymorphism in 104 Chinese Zang volunteers].
Ding HW; Dong WZ; Jiang ZG; Ma X
Yi Chuan; 2004 Mar; 26(2):151-4. PubMed ID: 15639978
[TBL] [Abstract][Full Text] [Related]
13. Differences in genotype and allele frequency distributions of polymorphic drug metabolizing enzymes CYP2C19 and CYP2D6 in mainland Chinese Mongolian, Hui and Han populations.
Yin SJ; Ni YB; Wang SM; Wang X; Lou YQ; Zhang GL
J Clin Pharm Ther; 2012 Jun; 37(3):364-9. PubMed ID: 21913948
[TBL] [Abstract][Full Text] [Related]
14. Allele and genotype frequencies of CYP3A4, CYP2C19, and CYP2D6 in Han, Uighur, Hui, and Mongolian Chinese populations.
Zuo LJ; Guo T; Xia DY; Jia LH
Genet Test Mol Biomarkers; 2012 Feb; 16(2):102-8. PubMed ID: 22224559
[TBL] [Abstract][Full Text] [Related]
15. CYP2C19 genotype and S-mephenytoin 4'-hydroxylation phenotype in a Chinese Dai population.
He N; Yan FX; Huang SL; Wang W; Xiao ZS; Liu ZQ; Zhou HH
Eur J Clin Pharmacol; 2002 Apr; 58(1):15-8. PubMed ID: 11956668
[TBL] [Abstract][Full Text] [Related]
16. S-mephenytoin hydroxylation phenotype and CYP2C19 genotype among Ethiopians.
Persson I; Aklillu E; Rodrigues F; Bertilsson L; Ingelman-Sundberg M
Pharmacogenetics; 1996 Dec; 6(6):521-6. PubMed ID: 9014201
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of lansoprazole in Chinese healthy subjects in relation to CYP2C19 genotypes.
Hu YR; Qiao HL; Kan QC
Acta Pharmacol Sin; 2004 Aug; 25(8):986-90. PubMed ID: 15301728
[TBL] [Abstract][Full Text] [Related]
18. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations.
Goldstein JA; Ishizaki T; Chiba K; de Morais SM; Bell D; Krahn PM; Evans DA
Pharmacogenetics; 1997 Feb; 7(1):59-64. PubMed ID: 9110363
[TBL] [Abstract][Full Text] [Related]
19. Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype.
Chang M; Dahl ML; Tybring G; Götharson E; Bertilsson L
Pharmacogenetics; 1995 Dec; 5(6):358-63. PubMed ID: 8747407
[TBL] [Abstract][Full Text] [Related]
20. A rapid and simple detection of genetic defects responsible for the phenotypic polymorphism of cytochrome P450 2C19.
Itoh K; Inoue K; Yanagiwara S; Kyoya H; Suzuki T
Biol Pharm Bull; 1999 Jan; 22(1):77-9. PubMed ID: 9989666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]